Key Points
This antiviral effect differs from most Vaccines currently under development which directly target the spike protein. The mode of action may offer a complementary treatment regime using therapeutics targeting the virus.
"Our initial results suggest the inhibitory substance/s in the products are binding to other antigens present on the SARS-CoV-2 virus which interfere with the mechanism the virus uses to gain entry and infect human cells. We do not yet know which compound/s in the products are responsible for this interference. However, we are excited to try and identify them," said Professor Lyras.
Prof Lyras further added, "it does not matter whether antagonists to the SARS-CoV-2 virus block the binding of the spike protein directly or indirectly as long as they can prevent or reduce infection."
The research team now plans to try and isolate and identify the inhibitory molecule/s in IMM124E.
The company is also pleased to announce the appointment of Dr Dan Peres as Chief Medical Officer. Dr Peres will be responsible for leading and managing the company's clinical development programs with a preliminary focus on COVID-19. Dr Peres was previously engaged by Immuron to manage the company sponsored NASH phase II clinical trial.
This release has been authorised by the directors of Immuron Limited.
| COMPANY CONTACT: Dr Jerry Kanellos, Ph.D. Chief Executive Officer Ph: +61 (0)3 9824 5254 [email protected] |
For more information visit: http://www.immuron.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
